You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Anti-XRCC4 antibody - ChIP Grade (ab145)

CodeSizePriceAbpointsAvailability
    
Add to basket
 

  • -

  •   
  •   
  •   

  •  

  •  
  •  

  •  

  •  
Updating...

Reassurance, Refunds & Replacements

If your product does not perform as described on this datasheet, we will refund or replace your product...

Read our guarantee »

Publishing research using ab145? Please let us know so that we can cite the reference in this datasheet

Show applications key

ab145 has been referenced in 7 publications.

  1. Roy S et al. XRCC4's interaction with XLF is required for coding (but not signal) end joining. Nucleic Acids Res 40:1684-1694 (2012). WB; Human. PubMed: 22228831
  2. Massip L et al. Deciphering the chromatin landscape induced around DNA double strand breaks. Cell Cycle 9:2963-72 (2010). ChIP; Human. PubMed: 20714222
  3. Berkovich E et al. Assessment of protein dynamics and DNA repair following generation of DNA double-strand breaks at defined genomic sites. Nat Protoc 3:915-22 (2008). PubMed: 18451799
  4. Bae NS & Baumann P A RAP1/TRF2 complex inhibits nonhomologous end-joining at human telomeric DNA ends. Mol Cell 26:323-34 (2007). PubMed: 17499040
  5. Berkovich E et al. Roles of ATM and NBS1 in chromatin structure modulation and DNA double-strand break repair. Nat Cell Biol 9:683-90 (2007). ChIP; Human. PubMed: 17486112
  6. Nabatiyan A et al. Induction of CAF-1 expression in response to DNA strand breaks in quiescent human cells. Mol Cell Biol 26:1839-49 (2006). ICC/IF; Human. PubMed: 16479003
  7. Deriano L et al. Human chronic lymphocytic leukemia B cells can escape DNA damage-induced apoptosis through the nonhomologous end-joining DNA repair pathway. Blood 105:4776-83 (2005). PubMed: 15718417

Publishing research using ab145? Please let us know so that we can cite the reference in this datasheet

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"